THURSDAY, 2 JULY 2020 | 13:15 – 14:15

MODERATOR
Michel Ducreux, MD, PhD
Professor of Medical Oncology
Head of GI Oncology Unit
Department of Medical Oncology
Inserm U1279
Team “Endocytosis, Cytoskeleton and Cell Migration”
Former Chairman
GI Group EORTC
Gustave Roussy Institute
Villejuif, France

PANELISTS
Richard S. Finn, MD
Professor of Medicine
Geffen School of Medicine
University of California Los Angeles
Los Angeles, California, United States

Lorenza Rimassa, MD
Associate Professor of Medical Oncology
Humanitas University
Deputy Director Medical Oncology Unit
Humanitas Clinical and Research Center - IRCCS Rozzano
Milan, Italy

Han Chong Toh, BSc, MB BCHIR, MRCP, FRCP, FAMS
Deputy Medical Director
National Cancer Centre Singapore
Singapore, Republic of Singapore

TARGET AUDIENCE
This activity is intended for non-US oncologists, gastroenterologists, hepatologists, interventional radiologists, surgeons, pathologists, and other physicians managing patients with hepatocellular carcinoma (HCC).

LEARNING OBJECTIVES
Upon completion of this activity, participants will:

• Have increased knowledge regarding the rationale behind using immunotherapy combination strategies for the treatment of unresectable HCC
• The latest efficacy and safety data investigating immunotherapy combination regimens for the frontline treatment of patients with unresectable HCC
• Demonstrate greater confidence in their ability to understand the clinical implications of the recent clinical trial data regarding frontline immunotherapy combination therapies for the patient with unresectable HCC

ACCREDITATION STATEMENT
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

AGENDA
13:15 Welcome and Introduction
Michel Ducreux, MD, PhD
13:17 Immunotherapy Combination Strategies in Unresectable HCC: Why Do We Need Combinations?
Lorenza Rimassa, MD
13:27 Translating the Latest Efficacy and Safety Data: What Does This Mean for Clinical Practice?
Michel Ducreux, MD, PhD
13:41 Clinical Cases With Unresectable HCC: What Are the Current and Emerging Options?
Richard S. Finn, MD
13:55 Discussing the Goals of Treatment for the Individual Patient: Sharing Experiences
Han Chong Toh, BSc, MB BCHIR, MRCP, FRCP, FAMS
14:05 Q&A and Concluding Remarks
Michel Ducreux, MD, PhD, and Panel
14:15 Adjourn

This symposium is not an official part of the World Congress scientific program, nor is it organized or endorsed by Imedex.
Supported by an independent educational grant from Roche.